CLINICAL AND PHARMACOKINETIC EQUIVALENCE OF ORIGINAL AND GENERIC AMLODIPINE IN PATIENTS WITH MILD-TO-MODERATE ARTERIAL HYPERTENSION
| Autor: | N. A. Belolipetskiy, S. N. Tolpygina, J. B. Zverkov, V. V. Pisarev, I. E. Koltunov, V. G. Belolipetskaya, S. J. Martsevich |
|---|---|
| Jazyk: | English<br />Russian |
| Rok vydání: | 2015 |
| Předmět: | |
| Zdroj: | Рациональная фармакотерапия в кардиологии, Vol 3, Iss 5, Pp 39-44 (2015) |
| Druh dokumentu: | article |
| ISSN: | 1819-6446 2225-3653 |
| DOI: | 10.20996/1819-6446-2007-3-5-37-39 |
| Popis: | Aim. To study clinical equivalence of two amlodipines under the control of their plasma levels and evaluate their pharmacoeconomical efficacy in patients with arterial hypertension (AH).Material and methods. 31 patient with AH were included in the study (14 men and 17 women). 21 (66 %) patients had AH of 1 stage and 10 (34 %) patients had AH of 2 stage. All patients were 39-81 y.o. (average - 60 y.o.) with AH duration 0,5-43 years (average - 17,9 years). Antihypertensive effect of Amlorus (Synthesis, Russia) and Norvasc (Pfizer, USA) was evaluated in the study. Blood pressure (BP), amlodipine plasma levels (by liquid chromatography with mass spectrometry) and side effects were registered before and after 2, 4 and 6 weeks of therapy. Hydrochlorothiazide 25 mg/d was added if the monotherapy with amlodipine10 mg/d had not been efficient. Therapy with the second studied amlodipine followed the therapy with the first drug.Results. Both drugs provided similar plasma amlodipine concentrations with significant BP reduction. 96,6 % and 90 % of patients reached BP target level ( |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|